Hepatitis B virus infection remains a major cause of morbidity and mortality worldwide as an estimated 350 million people are persistently infected with HBV.It makes HBV infection one of the most harzardoas viral diseases for humans and a global public health concern. Only in China the infection rate is 60-70 percent and chronically infected individuals are at risk for development of HBV-related complications such as end-stage liver cirrhosis or hepatocellular carcinoma, accounting for about 15-25 percent mortality.At present, two therapeutic agents are recommended for treatment of chronic hepatitis B virus,Interferon(include common and prolonged action)and nucleoside analogues such as lamivudine.But neither of them can clear covalently closed circular DNA(cccDNA) of HBV.After therapy was stopped,HBV DNA reappeared in most patients. So it is very important to treat the patients with HBV chronic infection with more effective therapies.It is worth noticing that all drug therapy depend on the level of patients' own immunology functiou too much,and their mechanisms of... |